Norwood Abbey subsidiary's technology to be evaluated by MedImmune

Question time with Professor Richard Boyd.

The first of 80 patients have been enrolled in Norwood Immunology's (AIM:NIM) phase II clinical trial using its thymus-rejuvenating technology in cancer patients receiving self-derived (autologous) bone marrow transplants.

Narhex Life Sciences (ASX:NLS) has signed a manufacturing contract with Indian, Nasdaq-listed company Dr Reddy's for initial GMP-grade production of the prodrug of Narhex's candidate HIV protease inhibitor, DG35.

Norwood Abbey's (ASX:NAL) Norwood Eyecare division is to partner with the University of Crete, in Greece, on R&D in the field of Epi-LASIK refractive surgery and related innovations.

Norwood Abbey (ASX:NAL) has initiated animal studies for the use of its needle-free injection device for delivering virosomes, potent carriers of antigens for vaccination.

Immune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has entered into an option to acquire all the share capital of Netherlands-based Bestewil Holding, the 100 per cent owner of Virosome Biologicals Group, for up to 25 million euros (AUD$40.5 million).

The Australian life sciences sector has picked up with small cap stocks seeing positive growth in the last quarter, according to the November edition of PricewaterhouseCoopers' quarterly BioForum report.

Immune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has revealed plans to seek an initial public offering (IPO) in the USA, subject to market conditions.

Melbourne-based Epitan (ASX:APT, ADR:EPTNY, XETRA:UR9) has filed for a full international patent to protect the commercial use of the topical formulation of its melanin producing drug EPT1647 (formerly Melanotan).

Norwood Devices, a division of medical technologies group Norwood Abbey (ASX:NAL) has received approval from the Russian Ministry of Health to import and sell the Norwood EyeCare Epi-LASIK system.